Insights

Press Releases
2023-06-29
FDA Acceptance of Drug Master File Marks New Milestone Achieved for OBiO TECH of GMP Plasmid Products
OBiO Technology (Shanghai) Corp., Ltd('OBiO', 688238. SH) is a biotechnology company focusing on the cell and genetherapy field. Recently announced that the U.S. Food and Drug Administration(FDA)
2023-04-29
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboratio
2023-04-24
A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology
SHANGHAI, April24, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology (Shanghai) Corp.,Ltd. ("OBiO" or "the Company"), a leading gene and celltherapy CDMO in China, announced the launching o
ALL PRESS RELEASES
Events
May 16-20, 2023
ASGCT 26TH ANNUAL MEETING
Los Angeles, CA
JUL 15-16, 2022
China Oncolytic Virus Conference 2022 (Hybrid)
SHANGHAI, China
MAY 16-19, 2022
ASGCT 25TH ANNUAL MEETING
WASHINGTON, D.C.
APR 15-16, 2022
SAPA-GP 2022 Annual Conference (Hybrid)
King of Prussia, PA

Inquiry

CDMO Solutions


scientific services

Request Now
© OBiO Tech, Inc. All Rights Reserved